{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:45:35Z","timestamp":1789623935510,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.humpath.2016.09.026","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T17:17:28Z","timestamp":1476897448000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"60","author":[{"given":"Stephanie M.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-346X","authenticated-orcid":false,"given":"James","family":"McElherne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keller-Ramey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wickii","family":"Vigneswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.09.026_bb0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2016.09.026_bb0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2016.09.026_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2008.02.013","article-title":"Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma","volume":"62","author":"Kobayashi","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2016.09.026_bb0020","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.09.026_bb0025","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/AJCPT94JVWIHBKRD","article-title":"Diagnostic usefulness of p16\/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis","volume":"139","author":"Wu","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0040","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ijc.29015","article-title":"Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI\/SNF genes","volume":"136","author":"Yoshikawa","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2016.09.026_bb0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2016.09.026_bb0050","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2016.09.026_bb0055","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JTO.0b013e31829e7ef9","article-title":"Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations","volume":"8","author":"Zauderer","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0060","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.09.026_bb0065","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma","volume":"10","author":"Iacono","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","article-title":"The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","article-title":"9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis","volume":"60","author":"Takeda","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2016.09.026_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.humpath.2016.09.026_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.humpath.2016.09.026_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gcc.22129","article-title":"Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases","volume":"53","author":"Pilarski","year":"2014","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.humpath.2016.09.026_bb0100","first-page":"1","article-title":"BAP1 hereditary cancer predisposition syndrome: a case report and review of literature","author":"Klebe","year":"2015","journal-title":"Biomark Res"},{"key":"10.1016\/j.humpath.2016.09.026_bb0105","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and p16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"Lopez-Rios","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.09.026_bb0110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2016.09.026_bb0115","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0120","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2016.09.026_bb0130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/PAS.0000000000000616","article-title":"BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2016.09.026_bb0140","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non\u2013small cell lung carcinomas from malignant mesothelioma","volume":"5","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2016.09.026_bb0145","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/annonc\/mdt135","article-title":"Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation","volume":"24","author":"Ribeiro","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.humpath.2016.09.026_bb0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.humpath.2016.09.026_bb0160","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/gcc.22381","article-title":"Different prognostic roles of tumor suppressor gene BAP1 in cancer: a systematic review with meta-analysis","volume":"55","author":"Luchini","year":"2016","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.humpath.2016.09.026_bb0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0180","first-page":"460A","article-title":"Combined use of p16 FISH and BAP1 immunohistochemistry optimizes diagnosis of malignant pleural mesothelioma [abstract 1913]","volume":"26","author":"McGregor","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.09.026_bb0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/dc.23491","article-title":"BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions","volume":"44","author":"Walts","year":"2016","journal-title":"Diagn Cytopathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716302519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:52:16Z","timestamp":1718833936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716302519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":37,"alternative-id":["S0046817716302519"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.09.026","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}